Femilis LNG IUS

Description: IUS releasing ~20mcg of levonorgestrel daily, expected to last for at least 5 years. In vitro study suggest constant rate of LNG release similar to the Mirena. Four products with the Femilis name have been developed. They are various sizes, contain different amounts of levonorgestrel, and have different durations of use.

Product Details

User: Female

Hormonal: Yes

Delivery Method: Intrauterine

Duration Type: Long-acting

Duration: 5 years

Dose: 20 mcg

Active Pharmaceutical Ingredient (API):
  • levonorgestrel

Multipurpose Preventive Technology (MPT): No

Status Details

Developer: Contrel Research, Belgium, APCOR R&M, Belgium

Project Phase: Limited Market Availability

Development Stage: Regulatory

Active Development: Yes

Additional Information

References:
  • Wildemeersch D, et al. (2005) Ease of insertion, contraceptive efficacy and safety of new T-shaped levonorgestrel-releasing intrauterine systems. Contraception. 71(6):465-9.

  • Wildemeersch D, et al. (2016) Femilis 60 Levonorgestrel-Releasing Intrauterine System-A Review of 10 Years of Clinical Experience. Clin Med Insights Reprod Health. 10: 19-27.

  • Wildemeersch D, et al. (2017) Results of a 5-year contraceptive trial in parous and nulliparous women with a new LNG-IUS. Gynecol Endocrinol. 33(3):223-226.

Vertical Tabs

Print